Welcome to 4DMedical, a leader in respiratory imaging solutions. We offer advanced software products that provide precise insights into lung function, helping pulmonary specialists diagnose and monitor respiratory conditions more accurately. Our technologies integrate easily with existing imaging systems, offering enhanced visualisation and quantification of airflow and lung dynamics without the need for contrast agents. Partnering with 4DMedical allows you to deliver high-quality, innovative care, ensuring the best possible outcomes for your patients.
View the entire 4DMedical portfolio.
Networking Opportunities: Connect with our team of specialists and fellow professionals to exchange ideas and insights
10-minute Lung Health Analysis Software Demonstrations
Join us for product demos of our analysis software, designed to give you new, actionable insights into lung health. Our tools are built to enhance your diagnostic capabilities and support better patient care.
This study investigates the use of X-ray Velocimetry (XV) to detect collateral ventilation (CV) in patients undergoing bronchoscopic lung volume reduction (BLVR) with endobronchial valves (EBV). It aimed to assess the predictive value of XV in detecting CV as incomplete CV can hinder EBV effectiveness. Read the Abstract
Presenter: Dr. Nina Eikelis
Authors: N. Eikelis, K. Nilsen, N. Marchetti, M. Rashid, P. Walia, H. Criner, C. Hatt, G. Criner
This study used X-ray Velocimetry (XV) to assess lung mechanics in ILD and COPD patients. The study demonstrated that XV provides a novel 3D approach to identifying disease-specific mechanical changes, aiding targeted interventions. Read the Abstract
Presenter: Dr Kris Nilsen
Authors: K. Nilsen, N. Eikelis, N. Marchetti, M. Rashid, P. Walia, H. Criner, C. Hatt, G. Criner
Bronchoscopic lung volume reduction (BLVR) is a guideline-approved treatment for advanced emphysema, but pneumothorax (PTX) remains a significant post-procedure complication. This study introduced novel lung stiffness measurements using X-ray Velocimetry (XV) to predict PTX risk. Read the Abstract
Presenter: Dr Kris Nilsen
Authors: K. Nilsen, N. Eikelis, N. Marchetti, M. Rashid, P. Walia, H. Criner, C. Hatt, G. Criner
Poster: Sunday, 23 March | 3:15–4:15 Exhibition Hall
Monday, 24 March | TSANZ Session 8:30–10:00 | 9:30–9:45 Room E3
Mucopolysaccharidoses (MPS) are lysosomal storage diseases characterized by glycosaminoglycan (GAG) accumulation, leading to respiratory dysfunction. While upper airway involvement is well-documented, middle and lower airway disease remains understudied. Using X-ray Velocimetry and flexiVent lung mechanics, we assessed respiratory function in an MPS I (Hurler syndrome) mouse model. Read the Abstract
Presenter: Assoc Professor Martin Donnelley
Authors: M. Donnelley, P. Cmielewski, R. Smith, P. Pirakalathanan, N. Eikelis, K. Nilsen, J. Louise, M. Lawrence, D. Parsons, K. Barratt, J. Logan, B Ung, D. Brooks, S. Orgeig and E. Parkinson-Lawrence
Poster: Sunday, 23 March | 4:15:–5:30 Exhibition Hall
X-ray Velocimetry (XV) is an advanced imaging technique that provides real-time regional ventilation measurements. This study aimed to assess XV’s ability to visualize and quantify ventilation changes following endobronchial valve (EBV) placement, a minimally invasive procedure for emphysema treatment. Read the Abstract
Presenter: Assoc Professor Martin Donnelley
Authors: R. Smith, C. Thomas, P. Nguyen, A. Badiei, N. Eikelis, K. Nilsen, D. Parsons, M. Donnelley
Poster: Sunday, 23 March | 4:15:–5:30 Exhibition Hall
This study aimed to assess the feasibility of X-ray Velocimetry (XV) as a non-invasive alternative to spirometry for assessing lung function in children with cystic fibrosis (CF) and controls. Children aged 3-18 underwent XV imaging alongside age-appropriate pulmonary function tests (PFTs). Read the Abstract
Presenter: Dr Jessica Phillips
Authors: J. Phillips, M. Bruorton, K. Carson-Chahhoud, D. Parsons, M. Donnelley, T. Goddard, J. House, A. Tai
Poster: Sunday, 23 March | 4:15:–5:30 Exhibition Hall
CTS: “Triage Unexplained Dispnea with Advanced Imaging”
Greg Mogel, MD, and David Westenkirchner, RRT, present advanced diagnostic software technologies, CT LVAS and LDAf. The webinar covers clinical applications for the ventilation and structural assessment software. Detailed lung ventilation assessments and the precise measurement of lung volumes and other parameters, including areas of abnormal tissue density, which can aid in making actionable diagnoses are also presented. Video includes demonstrations on how to integrate these technologies to effectively triage patients who present with unexplained dyspnea. The webinar concludes with a Q&A session.
.
American Journal of Respiratory and Critical Care Medicine: “Temporal Exploration of COPD Phenotypes: Insights from the COPDGene and SPIROMICS Cohorts”
A longitudinal analysis over five years showed that nearly 30% of patients experienced changes in their disease phenotypes, with a general trend of progression from subclinical disease toward emphysema. These findings inform personalized treatment approaches and improve clinical trials to slow disease progression.
“Novel Machine Learning Algorithm Predicts All-cause Mortality in the National Lung Screening Trial”
The study, presented at ATS 2024, introduces a novel machine learning algorithm designed to predict all-cause mortality among participants in the National Lung Screening Trial. This algorithm leverages a comprehensive set of variables, including imaging data and clinical information, to enhance predictive accuracy. By integrating these diverse data sources, the algorithm provides a robust tool for stratifying patient risk, potentially guiding clinical decision-making and optimizing patient management. Radiologists may find this approach particularly valuable as it highlights the potential of machine learning in augmenting traditional imaging practices and improving patient care outcomes in lung cancer screening programs.
Population Health Screening—Identifying and Re-engaging At-risk Patients
Emphysema and COPD are underdiagnosed in up to 50% of patients, and often not identified until advanced stages. For these patients, options like Bronchoscopic Lung Volume Reduction (BLVR) or Lung Volume Reduction Surgery (LVRS) can have a significantly positive impact on a patient’s quality of life.
B4 Symptoms, in collaboration with Lahey Hospital and Medical Center, a B4-sponsored pilot site, initiated a comprehensive screening program using 4DMedical’s advanced imaging analysis software, based on Imbio Technology. This program aims to identify patients who could benefit from BLVR and LVRS therapies for advanced emphysema.
